intrinsic coagulation pathway

in·trin·sic co·ag·u·la·tion path·way

(in-trin'zik kō-ag'yū-lā'shŭn path'wā)
A part of the coagulation pathway that is activated by contact of coagulation proteins with negatively charged surfaces. All components are within the bloodstream and include factors XII, XI, IX, VII, HMWK, and prekallikrein. The activated partial thromboplastin time tests for abnormalities in this pathway.
References in periodicals archive ?
Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.
Partial thromboplastin time (PTPT): On addition of phospholipids or surface active dispersed particles and calcium ions, thrombin formation occurs via the intrinsic coagulation pathway.
In addition, all patients were screened by several laboratory tests, including measurement of the complete blood count (CBC), including platelet count; prothrombin time (PT) to evaluate the extrinsic coagulation pathway (factor II, V, VII, and X activity), which were converted to calculate the International Normalized Ratio (INR) (7); and activated partial thromboplastin rime (aPTT) to evaluate the intrinsic coagulation pathway (factor VIII, IX, XI, and XII activity).
This fibrin clot forms via (1) the intrinsic coagulation pathway, when activated factor XII (FXIIa) binds to the exposed endothelial cells at the site of injury and (2) the extrinsic coagulation pathway, when small amounts of circulating FVIIa bind to tissue factor released from injured endothelial tissues.
The active protein in this fibrinolytic system is plasmin, which is produced as plasminogen and is activated by (1) kallikrein generated by the intrinsic coagulation pathway, (2) tissue plasminogen activator released from the injured endothelial cells, and (3) urokinase produced by kidney endothelial cells.
In May, TransTech announced the successful completion of Phase I clinical testing of its first drug candidate, TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, which is being developed as an anticoagulant for the treatment of thromboembolic disorders.
TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders.
The APTT assay is generally used in hospitalized patients for monitoring therapy with heparin and for the evaluation of disorders of the intrinsic coagulation pathway.